RESI Conference, Boston, Sep 2018, 36 pages Deal and Product Valuations Deal and Product Valuations
Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech
Continuing a trend that began in 2017, this year has seen the rise of big investment deals in the biotech sector. Smaller biotechs are also cashing in as Big Pharma look to fill dwindling pipelines; according to Bloomberg data, biotech acquisitions are expected to be at the highest level for 12 years. Analysing this data from … Continue reading Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech
Site Selection Report for Life Sciences Companies in Europe 2018
The new Site Selection Report for Life Sciences Companies in Europe, compiled by KPMG in association with Venture Valuation, explores the when, where and how of successful European expansion. The publication looks beyond site selection to include key work streams involved in successfully commercializing pharmaceutical products in Europe. In the 2018 edition, we identify five … Continue reading Site Selection Report for Life Sciences Companies in Europe 2018
RESI Conference June 2018 – Deal and Product Valuations
How to value a Biotech Start-up company
Biotech Investment Showcase, London, May 2018, 22 pages How to value a Biotech Start-up company
RESI Conference April 2018 – Deal and Product Valuations
Industry Insight: Valuations
Interviews with leading Life Sciences companies: Megakaryon Corporation
Current transfusion medicine entirely relies on donated blood. Megakaryon will change the transfusion practices by supplying safe and cost-saving platelets produced in vitro. Mass production in Japan is expected to begin in 2020. Venture Valuation (VV) interviewed Genjiro Miwa, CEO and Founder. Read the interview
Interviews with leading Life Sciences companies: tella inc.
Leveraging its proprietary technology of culturing highly purified dendritic cells (DCs), tella is developing, as its first immunotherapeutic product, a DC-based vaccine in combination with WT1 (Wilms’ tumor gene 1) antigen for inoperable pancreatic cancer. Venture Valuation (VV) interviewed Dr. Yuichiro Yazaki, President and CEO. Read the interview
The Launch of the BioAlberta Life Sciences Database
Zurich, Edmonton January 2018 BioAlberta, a Canadian life sciences industry organization, has recently become a new business partner of Venture Valuation/Biotechgate. BioAlberta gathers a flourishing biotech community comprised of around 170 life sciences companies, government organizations, support service providers, and research & academic institutions, situated across the province. As per the partnership agreement, Venture Valuation … Continue reading The Launch of the BioAlberta Life Sciences Database